Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

QURE

+ Watchlist+ Portfolio

uniQure N.V.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$20.78
52-Week Range
$8.73 – $51.72
Market Cap
$1.42B
P/E (TTM)
—
EPS (TTM)
-3.51
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.83
PEG Ratio
—
Return on Equity
-88.99%
Return on Assets
-13.70%
Gross Margin
0.00%
Operating Margin
-993.96%
Profit Margin
0.00%
Current Ratio
11.52
Debt/Equity
1.90
Total Debt
$559.64M
Free Cash Flow
$-167.19M
Revenue Growth
40.40%
Earnings Growth
—
Enterprise Value
$1.31B

Market Snapshot

About

uniQure is a Netherlands-based gene therapy biotechnology company focused on developing treatments for patients with severe genetic diseases. The company has a leading hemophilia B gene therapy candidate and a pipeline targeting other rare disorders. uniQure combines proprietary adeno-associated virus (AAV) technology with clinical development expertise to advance potentially curative one-time treatments.